As newly public biotechs stumble out of gate, 89bio, Centogene join IPO queue

89bio and Centogene B.V. filed on Friday to go public on NASDAQ in a week that saw two high profile offerings encounter headwinds after their debuts on the exchange.

NASH company 89bio Inc. proposed to raise up to $70 million in an offering underwritten by BofA Merrill Lynch, SVB Leerink, RBC Capital Markets and Oppenheimer...